Cutaneous autoimmune diseases during COVID-19 pandemic

Editor

The pandemic of infection with the severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing the atypical pneumonia coronavirus disease 19 (COVID-19) has become a global health emergency. In parallel with the spread of the infection, there is new information on cutaneous involvement reminiscent to autoimmune diseases and concerns about the risk of disease and management of patients with cutaneous autoimmunity under immunosuppression.

COVID-2019 mainly presents with fever, cough, loss of smell and taste, myalgia and fatigue. Main complication of the infection is progression to acute respiratory distress syndrome (ARDS), coagulopathy, vasculopathy, cardiovascular failure and a cytokine storm syndrome requiring intensive care for days or even weeks.

The risk factors for more severe COVID-19 infection are cardiovascular illnesses, diabetes, renal failure, respiratory failure, morbid obesity and older age (>65). Cutaneous symptoms of COVID-19 include petechial skin rash or digitate scaly thin plaques associated with severe respiratory disease (Table 1). A maculopapular urticarial rash may present as early sign of disease or during disease without a yet known association to severity. There was also a case of pityriasis rosea like rash in one patient with mild febrile COVID-19. In young children, infection with SARS-CoV-2 can be associated with Kawasaki syndrome including the maculopapular oedematous rash and conjunctival injection.

Mild forms of disease in younger individuals seem to present with chilblain-like lesions on acral locations especially the toes (Table 1). The skin appears shiny red and is painful (Fig. 1). The lesions resolve spontaneously after weeks and indicate a rather favourable outcome. In histological section, these lesions may have a slight vacuolar

| Table 1 Cutaneous lesions associated with COVID-19 |
|-----------------------------------------------|
| Cutaneous findings                          | Histopathology                                                                 | COVID-19                                      | Reference          |
| Acral chilblain lesions                      | Vacuolar interface dermatitis and superficial and deep perivascular and periadnexal lymphohistiocytic infiltrates | Mild or none, late symptom                    | 17–19,21,27         |
| Violaceous papules and digital swelling      | Diffuse perivascular involvement of the dermis and hypodermis by a dense lymphoid infiltrate | Mild or none, late symptom                    | 20                 |
| Symmetrical petechial skin rash on buttocks, thighs that might be similar to dengue virus exanthema | Superficial perivascular infiltrate with erythrocyte extravasation, dermal papillary oedema, and scattered dyskeratotic keratinocytes | Associated with severe acute respiratory syndrome | 5,6               |
| Digitate scaly thin plaques                  | Spongiosis in the epidermis and mild papillary oedema with lymphohistiocytic infiltrate in the dermis | Associated with severe acute respiratory syndrome | 7                  |
| Erythematous and oedematous non-pruritic annular fixed plaques involving the upper limbs, chest, neck, abdomen and palms | Superficial perivascular lymphohytic infiltrate, papillary dermal oedema, mild spongiosis, lichenoid and vascular interface dermatitis, dyskeratotic basilar keratinocytes | Mild              | 9                  |
| Maculopapular and urticarial rash            | Early symptom                                                                  | Mild, associated mild lung disease            | 11,13              |
| Maculopapular symmetrical rash               | Superficial perivascular lymphohytic infiltrate, papillary dermal oedema, ectatic vessels, vascular interface dermatitis | Kawasaki syndrome associated with COVID-19    | 15                 |
| Maculopapular rash in young children         |                                                                               | Mild                                          | 14                 |
| Pityriasis rosea                             |                                                                               |                                               |                    |

DOI: 10.1111/jdv.16749

© 2020 European Academy of Dermatology and Venereology
interface dermatitis and a superficial and deep perivascular and periadnexal lymphohistiocytic infiltrate. Reports from Italy and France documented an outbreak of chilblain-like lesions contemporarily to COVID-19 epidemic. Despite the low rate of positive mRNA or antibody testing, the coincidence of both events is highly suggestive for direct correlation. The induction of the lesions might be related to a direct viral effect, pathogenic priming or mediated by upregulation of the antiviral cytokine type I interferon. Type I interferons cause a stimulation and activation of the immune response and a thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Patients with high levels of type I interferon-mediated autoimmune diseases or type I interferonopathies frequently develop chilblain lesions.

Chilblain or erythema multiforme like acral ischaemic lesions were also observed contemporarily to COVID-19 epidemic in Spain. None of the 132 patients reported developed COVID-19 pneumonia or any other complication. The authors hypothesize that the latency time of up to 30 days between mild COVID-19 symptoms and skin manifestations, and the low positive rate for nasopharyngeal swabs (only 2 positive results) suggest that these chilblain-like ischaemic lesions represent a late manifestation of SARS-CoV-2 infection.

There are no large reports on the frequency of infection or the risk of severe COVID-19 in patients with autoimmune diseases involving the skin such as lupus erythematosus, dermatomyositis, systemic sclerosis and autoimmune bullous diseases (Table 2). Currently, limited data suggest that patients with autoimmune disorders, especially rheumatoid arthritis, and immunosuppression do not appear to be more severely infected by COVID-19.

However, immunosuppression and especially long-term hydroxychloroquine treatment did not prevent infection of lupus patients. These patients may get infected and can also suffer from severe COVID-19 if they have concomitant risk factors such as obesity or chronic kidney disease (Table 2).

Immunosuppressive treatment is necessary for the management of autoimmune diseases, and it is known from patients with rheumatoid arthritis that the risk for viral infection is increased if the disease is not controlled. Therefore, we should continue immunosuppressive treatment in patients with autoimmune diseases and not postpone diagnostic procedures if ever possible. There are concerns especially regarding the long-term immunosuppressive effect of

| Autoimmune disease (number of patients) | Relevant comorbidities† | Ongoing treatment | Outcome 19 | Reference |
|----------------------------------------|-------------------------|-------------------|------------|-----------|
| Systemic sclerosis (1)                 | Yes                     | Tocilizumab       | Mild       | 38        |
| Granulomatosis with polyangiitis (1)   | Yes                     | Rituximab         | ARDS, survived | 39       |
| Systemic lupus erythematosus (17)      | Yes                     | Hydroxychloroquine, other immuno suppressives interrupted | 14 admitted to hospital, 2 died | 40       |
| Rheumatoid arthritis, spondyloarthritis (4) | Yes                  | DMARDs, temporarily withdrawn | 3 mild, 1 hospitalized, survived | 41       |
| Systemic sclerosis (1 with positive swab of 123 total patients with connective tissue diseases), Psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, Crohn’s disease and ankylosing spondylitis under (86) | Yes                     | Hydroxychloroquine, rituximab | severe pneumonia, died | 42       |
| Psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, Crohn’s disease and ankylosing spondylitis under (86) | Yes                     | Methotrexate, hydroxychloroquine, JAK inhibitors, TNF inhibitor or IL-17-, IL-23-, IL-12/23 blocker | mild, 14 admitted to hospital, 1 died | 43       |
| Pemphigus vulgaris (1)                 | None                    | Mycophenolate mofetil | Nausea and fever, mild | 44       |
| Psoriasis (1)                         | None                    | IL-17 inhibitor   | No symptoms | 45        |
| Psoriasis, arthritis, Crohn (1)       | None                    | IL-23 inhibitor   | Mild        | 46        |

DMARDs, methotrexate, etanercept, tocitacinib, leflunomide, abatacept; IL, interleukin.

†Older age > 65, obesity, cardiovascular disease, diabetes, kidney disease, lung disease, smoker.
rituximab used for treatment of pemphigus. The initiation of rituximab in patients with autoimmune bullous disease must be weighed against the risks of conventional immunomodulatory regimens on an individual basis.

To reduce the risk of infection routine face-to-face appointments could be delayed if they are not urgently needed or substituted by teledermatology. Patients should be encouraged to update appropriate flu and pneumococcal vaccination and maintain the hygiene and protection measures.

To improve current knowledge on the disease course of COVID-19 in patients with autoimmune disease, their risk of infection and potential treatment options, all cases should be reported to the COVID-19 registries set by organization such as the EULAR, EUSTAR, task force for autoimmune bullous diseases, the German network for systemic sclerosis and local epidemiology registries.

Acknowledgement
The patient in this manuscript has given written informed consent to the publication of his case details.

Conflicts of interest
The authors have declared no conflict of interest.

Funding source
This work was supported by the Deutsche Forschungsgemeinschaft (German Research Foundation), grant 369799452/404458960 to CG.

C. Günther,* R. Aschoff, S. Beissert
Department of Dermatology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany

*Correspondence: C. Günther. E-mail: claudia.guenther@ukdd.de

References
1 Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.
2 Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med 2020; 382: e102.
3 Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–1062.
4 Ackermann M, Verleden SE, Kuehnel M et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020. https://doi.org/10.1056/NEJMoa2015432
5 Diaz-Guirraena B, Dominguez-Santos M, Suarez-Valle A et al. Petechial skin rash associated with severe acute respiratory syndrome coronavirus 2 infection. JAMA Dermatol 2020. https://doi.org/10.1001/jamadermatol.2020.1741
6 Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue. J Am Acad Dermatol 2020; 82: e177.
7 Sanchez A, Sohier P, Benghanem S et al. Digitate papulosquamous eruption associated with severe acute respiratory syndrome coronavirus 2 infection. JAMA Dermatol 2020. https://doi.org/10.1001/jamadermatol.2020.1704
8 Henry D, Ackerman M, Sanclemne E, Finon A, Esteve E. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol 2020; 34: e244–e245. https://doi.org/10.1111/jdv.16472
9 Amatore F, Macagno N, Mailhe M et al. SARS-CoV-2 infection presenting as a febrile rash. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16528
10 van Damme C, Berlingin E, Saussez S, Accaputo O. Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16523
11 Avellan Moreno R, Villa E, Avellan Moreno V, Estela Villa C, Aparicio M, Fontanella A. Cutaneous manifestation of COVID-19 in images: a case report. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16531
12 Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020; 34: e212–e213. https://doi.org/10.1111/jdv.16387
13 Mahé A, Birckel E, Krieger S, Merklen C, Bottlaender L. A distinctive skin rash associated with coronavirus disease 2019. J Eur Acad Dermatol Venereol 2020; 34: e246–e247. https://doi.org/10.1111/jdv.16471
14 Ehssani AH, Nasimi M, Bigdelo Z. Pityriasis rosea as a cutaneous manifestation of COVID-19 infection. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16579
15 Jones VG, Mills M, Suarez D et al. COVID-19 and Kawasaki disease: novel virus and novel case. Hospital Pediatrics 2020; 10: 537–540.
16 Viner RM, Whittaker E. Kawasaki-like disease: emerging complication during the COVID-19 pandemic. Lancet 2020; 395: 1741–1743.
17 Landa N, Mendieta-Eckert M, Fonda-Pascual P, Aguirre T. Chilblain-like lesions on feet and hands during the COVID-19 pandemic. Int J Dermatol 2020; 59: 739–743.
18 Kolivras A, Dehavay F, Delplace D et al. Coronavirus (COVID-19) infection-induced chilblains: a case report with histopathologic findings. JAAAD Case Rep 2020; 6: 489–492.
19 Piccolo V, Neri I, Filippeschi C et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16526
20 Recalcati S, Barbaggal T, Frasin LA et al. Acral cutaneous lesions in the time of COVID-19. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16533
21 Bouazza J, Duong T, Jachiet M et al. Vascular skin symptoms in COVID-19: a French observational study. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16544
22 Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. J Trans Autoimmun 2020; 3: 100051.
23 Kavanagh D, McGlasson S, Jury A et al. Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood 2016; 128: 2824–2833.
24 Zimmermann N, Wolf C, Schwenke R et al. Assessment of clinical response to janus kinase inhibition in patients with familial chilblain lupus and TREX1 mutation. JAMA Dermatol 2019; 155(3): 342–346. https://doi.org/10.1001/jamadermatol.2018.5077
25 Gunther C, Berndt N, Wolf C, Lee-Kirsch MA. Familial chilblain lupus due to a novel mutation in the exonuclease III domain of 3’ repair exonuclase 1 (TREX1). JAMA Dermatol 2015; 151: 426–431.
26 Lee-Kirsch MA. The type I interferonopathies. Annu Rev Med 2017; 68: 297–315.
27 Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A et al. Characterization of acute aco-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak. J Am Acad Dermatol 2020; 83(1): e61–e63. https://doi.org/10.1016/j.jaad.2020.04.093
28 Monti S, Balduzzi S, Delvino P, Bellis E, Quadrrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020; 79: 667–668.
29 Favalli EG, Agape E, Caporali R. Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis. J Rheumatol 2020; 47. https://doi.org/10.3899/jrheum.200507
30 D’Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transplant 2020; 26: 832–834.
31 Mathian A, Mahervas M, Rohmer J et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis 2019; 78: 837–839.
32 Bozzalla Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L. COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by teledmedicine. Ann Rheum Dis 2020. https://doi.org/10.1136/annrheumdis-2020-217717
33 Au K, Reed G, Curtis JR et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 785–791.
34 Shakhshouk H, Daneshpazhooh M, Murrell DF, Lehman JS. Treatment considerations for patients with pemphigus during the COVID-19 pandemic. J Am Acad Dermatol 2020; 82: e255–e256.
35 Kasperkiewicz M, Schmidt E, Fairley JA et al. Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/ctd.14625
36 Misra DP, Agarwal V, Gasparayan AY, Zimba O. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 2020; 39: 2055–2062.
37 Gianfrancesco MA, Hyrick KL, Gossec L et al. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol 2020; 2: e250–e253.
38 Mihai C, Dobrot A, Schröder M et al. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis 2020; 79: 668–669.
39 Guilpain P, Le Bihan C, Foulonne V et al. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. Ann Rheum Dis 2020. https://doi.org/10.1136/annrheumdis-2020-217549
30 Mathian A, Mahervas M, Rohmer J et al. Clinical Course of Coronavirus Disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis 2020; 79: 837–839.
41 Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical Course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020; 79: 667–668.
42 Favalli EG, Agape E, Caporali R. Incidence and Clinical Course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis. J Rheumatol 2020; 47. https://doi.org/10.3899/jrheum.200507
43 Haberman R, Axelrad J, Chen A et al. COVID-19 in immunede-mediated inflammatory diseases – case series from New York. N Engl J Med 2020. https://doi.org/10.1056/NEJMc2009567
44 Balestri R, Rech G, Girardelli CR. Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/1660-059X.14578
45 Balestri R, Rech G, Girardelli CR. SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/1660-059X.14571
46 Messina F, Piaserico S. SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor. J Eur Acad Dermatol Venereol 2020; 34: e254–e255. https://doi.org/10.1111/ctd.14648

DOI: 10.1111/ctd.146753

Occupational skin disease during the COVID-19 pandemic, as captured in a Dermatology staff clinic in the United Kingdom

Editor,

A dermatology walk-in clinic available to all hospital staff (HS) was commenced to treat skin problems related to personal protective equipment (PPE) during the COVID-19 pandemic. An observational case series was conducted in a single district general hospital within Wales (United Kingdom) to record the dermatological diagnoses. Our participant sample is comprised of clinical and non-clinical staff working in COVID-19 and non-COVID-19 areas of the hospital. Over the data collection period (6 weeks), a total of 72 patients attended the clinic of whom 62 were females and 10 were males (mean age = 43 years). Data are comprised of demographic data, current occupation (shown in Table 1), duration of symptoms, past medical history, regular medication and treatment interventions. An analysis of the clinical diagnoses seen is reported in Table 2.

Irritant hand dermatitis caused by increased frequency in hand washing and use of alcohol-based hand sanitizers was the most common symptom, affecting 62.5% of patients in agreement with previous research.1 Similar to Balato et al.,1 our treatment regimen advised regular applications of fragrance-free emollients. To improve treatment acceptance and compliance, we offered a lighter emollient (cream or lotion) to be applied during the day and a lipid-rich emollient (ointment) to be applied at home. We recommended the use of a topical steroid preparation for patients with inflamed skin. Information leaflets were provided, and soap substitutes were suggested for home use. Soap substitutes have not been validated to eradicate SARS-CoV-2 and therefore were not proposed for use in the work environment, as supported by the British Society of Cutaneous Allergy guidance.2

Pressure-related facial symptoms, due to mask usage, were also seen in 3 patients (4%) but not observed in as high percentages as Jiang et al.3 Our participant inclusion criteria included all staff rather than only staff caring for COVID-19 patients, and advice had been provided for the prevention of adverse effects, which could explain the difference. Skin protectant film was issued to staff for use prior to mask application and instructions about daily use of an emollient as a skin barrier and avoidance of mask overtightening was given. Facial cutaneous symptoms can lead to more frequent facial touching for relief of mechanical pressure, therefore increasing the risk of infection. We offered hydrocolloid dressings for use on pressure points on the face. To ensure an appropriate mask seal is not compromised by this intervention, a repeat ‘fit mask testing’ with the dressings already applied was recommended. Worsening of pre-existing skin conditions was managed following standard treatment of care.